These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18463510)

  • 1. Changes in retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (avastin) therapy.
    Prager F; Michels S; Simader C; Geitzenauer W; Schmidt-Erfurth U
    Retina; 2008 May; 28(5):682-8. PubMed ID: 18463510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration.
    Ozdemir H; Karacorlu M; Senturk F; Karacorlu SA; Uysal O
    Acta Ophthalmol; 2012 Feb; 90(1):71-5. PubMed ID: 20163371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.
    Moshfeghi AA; Rosenfeld PJ; Puliafito CA; Michels S; Marcus EN; Lenchus JD; Venkatraman AS
    Ophthalmology; 2006 Nov; 113(11):2002.e1-12. PubMed ID: 17027972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.
    Yodoi Y; Tsujikawa A; Nakanishi H; Otani A; Tamura H; Ojima Y; Hayashi H; Yoshimura N
    Am J Ophthalmol; 2009 May; 147(5):816-24, 824.e1. PubMed ID: 19211092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.
    Bashshur ZF; Haddad ZA; Schakal AR; Jaafar RF; Saad A; Noureddin BN
    Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
    Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
    Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
    Weigert G; Michels S; Sacu S; Varga A; Prager F; Geitzenauer W; Schmidt-Erfurth U
    Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study.
    Geitzenauer W; Michels S; Prager F; Rosenfeld PJ; Kornek G; Vormittag L; Schmidt-Erfurth U
    Retina; 2008; 28(10):1375-86. PubMed ID: 18784625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.
    Michels S; Rosenfeld PJ; Puliafito CA; Marcus EN; Venkatraman AS
    Ophthalmology; 2005 Jun; 112(6):1035-47. PubMed ID: 15936441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Chan CK; Meyer CH; Gross JG; Abraham P; Nuthi AS; Kokame GT; Lin SG; Rauser ME; Kaiser PK
    Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased electroretinogram a-wave amplitude after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Skaat A; Solomon A; Moroz I; Hai OV; Rechtman E; Vishnevskia Dai V; Rotenstreich Y
    Acta Ophthalmol; 2011 May; 89(3):e269-73. PubMed ID: 20946333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.